According to the Zhitong Finance App, Shiyao Innovation (300765.SZ) released its 2026 semi-annual results forecast. Net profit attributable to shareholders of listed companies is expected to be 1.18 billion yuan to 1.36 billion yuan in the first half of the year, turning a year-on-year loss into a profit.

During the reporting period, the company continued to increase investment in R&D and innovation, focusing on cutting-edge technology platforms such as antibody drugs, ADC and mRNA vaccines, and steadily advancing the R&D and industrialization process of the biopharmaceutical business pipeline. The product layout covered various core treatment fields such as tumors, metabolic and autoimmune diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.